Martin Case

Title: Martin Case - Innovator in IAP Binding Compounds

Introduction

Martin Case is an accomplished inventor based in Essex Junction, Vermont. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that target cellular IAPs (inhibitor of apoptosis proteins). His innovative work has the potential to impact therapeutic and diagnostic applications.

Latest Patents

Martin Case holds a patent for IAP binding compounds. These compounds are designed to bind to cellular IAPs, which play a crucial role in regulating apoptosis. The compounds are mimetics of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABOLO, IIid, Grim, and Reaper. They interact with a specific surface groove of IAP, providing a novel approach to manipulating apoptosis pathways. The patent also includes methods for using these compounds in therapeutic, diagnostic, and assay purposes.

Career Highlights

Martin Case is affiliated with Princeton University, where he continues to advance his research in biochemistry and molecular biology. His work has garnered attention for its innovative approach to understanding and manipulating cellular processes.

Collaborations

Martin has collaborated with notable colleagues, including George McLendon and Rachael A Kipp, who share his passion for scientific discovery and innovation.

Conclusion

Martin Case is a pioneering inventor whose work on IAP binding compounds represents a significant advancement in the field of biochemistry. His contributions have the potential to lead to new therapeutic strategies and diagnostic tools.